VivoSeq
Cardiovascular

Atrial Fibrillation (AF)

4

Pipeline Programs↗

17

Active Trials↗

5

Companies Involved↗

Atrial Fibrillation (AF) is an early-stage landscape with 4 programs across 5 companies. The most active players are Bristol-Myers Squibb, Regeneron, Anthos Therapeutics, Inc.. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

41/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Regeneron logo

Regeneron

2 programs

Phase 3A

Anthos Therapeutics, Inc.

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3L

Larisa Tereshchenko, MD, PhD

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Apixaban

Bristol-Myers Squibb

Phase 33

REGN7508

Regeneron

REGN9933

Regeneron

Abelacimab

Anthos Therapeutics, Inc.

Approved
No programs

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 67% of 6 pipeline programs.

Analysis

Trial Status

18

clinical trials

Recruiting9 · 50%
Not yet recruiting5 · 28%
Active, not recruiting3 · 17%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

18 trials

Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
Recruiting·AAbbott Medical Devices·Preclinical·NCT07523620·240 enrolled
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Recruiting·AAnthos Therapeutics, Inc.·Phase 3·NCT05712200·2,500 enrolled
ELectrocardiographic Imaging-guided Substrate Ablation in Patients With Atrial Fibrillation - a PILOT Study of a Personalized Therapy
Recruiting·HHospital Clinic of Barcelona·Preclinical·NCT07358611·30 enrolled
A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS)
Recruiting·Regeneron logoRegeneron·Phase 2·NCT07175428·1,200 enrolled
Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly (WISER-AF)
Recruiting·BBeijing Anzhen Hospital·Preclinical·NCT07403760·136 enrolled
A Global Randomized Trial Comparing Pulsed Field Ablation of Pulmonary Veins Plus Extra-PV Sources Utilizing Electrographic Flow Mapping Versus Pulmonary Veins Plus Posterior Wall in Persistent Atrial Fibrillation Patients.
Recruiting·BBoston Scientific Corporation·Preclinical·NCT07187115·699 enrolled
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation - Europe, Middle East and Africa [OPTION-EMEA]
Recruiting·BBoston Scientific Corporation·Preclinical·NCT07349121·500 enrolled
WATCHMAN FLX Pro European Registry
Recruiting·BBoston Scientific Corporation·N/A·NCT07262255·1,000 enrolled
A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, Versus Placebo in Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)
Recruiting·Regeneron logoRegeneron·Phase 3·NCT07430956·2,628 enrolled
Atrial Fibrillation Mapping Using Phase-Aligned Spectral Filtering for Decomposing Spatiotemporal Dynamics
Active, not recruiting·LLarisa Tereshchenko, MD, PhD·N/A·NCT06892561·336 enrolled
Comparison of Commercially Available 7-Day ECG Patches: A Randomized Study
Active, not recruiting·MMedical University Innsbruck·Preclinical·NCT07564349·150 enrolled
FARAPULSE Workflow Assessment Registry
Active, not recruiting·BBoston Scientific Corporation·N/A·NCT06656884·524 enrolled
A Researcher-initiated, Prospective, Open-label, Randomized Controlled Trial With a Parallel Design to Investigate the Prognostic Impact of Wearable Device-assisted Remote Management in Patients With Acute Heart Failure Complicated by Atrial Fibrillation
Not yet recruiting·BBeijing Anzhen Hospital·Preclinical·NCT07687862·818 enrolled
Cardiologist-Administered Midazolam vs. Anaesthesiologist-Assisted Propofol Sedation For Transoesophageal Echocardiography-Guided Cardioversion of Atrial Fibrillation (CARDIOZOLAM-1)
Not yet recruiting·GGødstrup Hospital·Approved·NCT07571447·220 enrolled
BOdygUardian MOnitoriNg for ReCurrencE of AF (BOUNCE-AF)
Not yet recruiting·Heart Rhythm Clinical and Research Solutions, LLC·N/A·NCT07671677·100 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)